Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
20-year-old who threatened German train attack remanded in custody - 21st human missions to Mars should hunt for signs of life, report says
- 3Arrow Exploration brings new Colombian oil well on stream ahead of schedule and under budget
- 4Sydney Sweeney's American Eagle campaign and Kendrick Lamar's Super Bowl performance were among the 10 biggest pop-culture moments of 2025
- 5Two Indonesian UN peacekeepers killed in explosion in Lebanon
- Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- IAF intercepts over 90% of drones launched by Iran, Hezbollah during Operation Roaring Lion
- French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- Well known Tea Brands for Each Tea Sweetheart
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- How did I get my own unique set of fingerprints?
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- IDF confirms Iranian missile fragments hit near Kirya, multiple cars ablaze in Ramat Gan
- Which Diet Prompts the Incomparable Wellbeing Results?
